Search
- Jan 10
Tarsus' CEO on the launch XDEMVY and additional programs that will be reading out in 2024
Bobby Azamian provides an update on the commercial launch of XDEMY in demodex blepharitis, and discusses additional programs.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A